- Home
- CUE vs FORA Comparison
CUE vs FORA Comparison
Compare CUE & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- FORA
- Stock Information
- Founded
- CUE 2014
- FORA 2014
- Country
- CUE United States
- FORA United States
- Employees
- CUE N/A
- FORA N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- FORA Computer Software: Prepackaged Software
- Sector
- CUE Health Care
- FORA Technology
- Exchange
- CUE Nasdaq
- FORA Nasdaq
- Market Cap
- CUE 60.6M
- FORA 62.7M
- IPO Year
- CUE 2018
- FORA N/A
- Fundamental
- Price
- CUE $0.92
- FORA $2.00
- Analyst Decision
- CUE Strong Buy
- FORA Strong Buy
- Analyst Count
- CUE 4
- FORA 1
- Target Price
- CUE $4.75
- FORA $5.00
- AVG Volume (30 Days)
- CUE 154.3K
- FORA 8.9K
- Earning Date
- CUE 05-08-2025
- FORA 03-27-2025
- Dividend Yield
- CUE N/A
- FORA N/A
- EPS Growth
- CUE N/A
- FORA N/A
- EPS
- CUE N/A
- FORA N/A
- Revenue
- CUE $9,532,000.00
- FORA $19,709,723.00
- Revenue This Year
- CUE $73.11
- FORA N/A
- Revenue Next Year
- CUE $11.02
- FORA $13.59
- P/E Ratio
- CUE N/A
- FORA N/A
- Revenue Growth
- CUE 149.53
- FORA N/A
- 52 Week Low
- CUE $0.45
- FORA $1.96
- 52 Week High
- CUE $2.26
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- CUE 33.15
- FORA 42.64
- Support Level
- CUE $0.95
- FORA $2.05
- Resistance Level
- CUE $1.03
- FORA $2.13
- Average True Range (ATR)
- CUE 0.08
- FORA 0.10
- MACD
- CUE 0.01
- FORA 0.00
- Stochastic Oscillator
- CUE 3.85
- FORA 0.00
Stock Price Comparison Chart: CUE vs FORA
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.